Latest Breaking News On - Global head of clinical development - Page 6 : comparemela.com

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)

United statesTim batemanFrancois tranquartCenters for diseaseRadiologic imaging program at saint luke hospitalLantheus holdings incGlobal head of clinical developmentAmerican society of nuclear cardiologyGe healthcareCoronary artery diseaseAmerican societyNuclear cardiologyPositron emission tomographySingle photon emission computed tomographyMyocardial perfusion imagingLabel study

GE Healthcare, Lantheus: Trial Finds Flurpiridaz PET Radiotracer Could Improve CAD Detection

FAIRFIELD (dpa-AFX) - GE Healthcare, the healthcare business of conglomerate General Electric Co. (GE), along with Lantheus Holdings Inc. (LNTH) announced Tuesday that the recent Phase III clinical

United statesFrancois tranquartLantheus holdings incMore such health newsGlobal head of clinical developmentAmerican society of nuclear cardiologyGe healthcareGeneral electricLantheus holdingsFlurpiridaz positron emission tomographyCoronary artery diseaseGlobal headClinical developmentPharmaceutical diagnosticsSingle photon emission computed tomographyPerfusion imaging

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary

United statesNew jerseyTim batemanDebbie levenFrancois tranquartMark kinarneyCenters for diseaseGlobal head of clinical developmentCorporate communicationsLantheus holdings incAmerican society of nuclear cardiologyGe healthcareCoronary artery diseasePerfusion imagingMolecular imagingAmerican society

Gilead Sciences s (GILD) Kite Announces Yescarta CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity

Gilead Sciences s (GILD) Kite Announces Yescarta CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrederickl lockeFrank neumannAmerican society of clinical oncologyMarrow transplant researchOncology program at moffitt cancer centerGilead company nasdaqDrug administrationInternational bloodGlobal head of clinical developmentAfrican american patients experienced longer timeInfusion comparedWhite patientsPossibly impacting overallComplete response ratesMore study

Syneos Health Names Michelle Keefe as Next Chief Executive Officer

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michelle Keefe as CEO and a member of the Company’s Board of Directors. Keefe, currently President, Medical Affairs and Commercial Solutions, succeeds Alistair Macdonald, who will .

Alistair macdonaldJohn dineenMichael brooksMichelle keefePrior to syneos healthSeton hall universityNurse serviceGlobal head of clinical developmentGlobal groupCarolina state universityClinical developmentHealth sciencesCompany reports first quarterPublicis healthCompany investor relationsCompany board of directors